Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus DRAXIMAGE MDP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus DRAXIMAGE MDP 25.
DRAXIMAGE DTPA vs DRAXIMAGE MDP-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical